Search results
Results from the WOW.Com Content Network
This is a complete list of estrogens and formulations that are approved by the FDA Tooltip Food and Drug Administration and available in the United States. Estrogens are used as hormonal contraceptives, in hormone replacement therapy, and in the treatment of gynecological disorders.
This is a list of progestogens (progesterone and progestins) and formulations that are approved by the FDA Tooltip Food and Drug Administration in the United States. Progestogens are used as hormonal contraceptives, in hormone replacement therapy for menopausal symptoms, and in the treatment of gynecological disorders.
Letrozole, sold under the brand name Femara among others, is an aromatase inhibitor medication that is used in the treatment of breast cancer for post-menopausal women. [1]It was patented in 1986 and approved for medical use in 1996. [4]
U.S. health regulators on Friday approved a new type of drug for women dealing with uncomfortable hot flashes caused by menopause. The Food and Drug Administration approved the once-a-day pill ...
A New Drug Application of bremelanotide for female sexual dysfunction was accepted by the US Food and Drug Administration (FDA) in June 2018, with a Prescription Drug User Fee Act (PDUFA) goal date set for 23 March 2019. [30] It was approved for use in the United States in June 2019. [3] [31] [32]
The FDA said Novo Nordisk's semaglutide, which is sold as Ozempic to treat diabetes and Wegovy for weight loss, remains on the agency's drug shortage list even though all versions of the drug are ...
Zoledronic acid is used for the treatment of osteoporosis in men and post-menopausal women at increased risk of fracture. [13] [14] In 2007, the US Food and Drug Administration (FDA) approved zoledronic acid for the treatment of postmenopausal osteoporosis. [7] [15]
Currently, there are two FDA-approved hair loss medications available for women: minoxidil, a topical solution sold over-the-counter, and Ritlecitinib, an oral prescription medication that was ...